Xiangru Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiangru Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Boyuan Wang
Research Department The Ninth Medical Center, Chinese PLA General Hospital Olympic Village Street Beijing China
1 shared publication - Hong-Yan Cai
Research Department The Ninth Medical Center, Chinese PLA General Hospital Olympic Village Street Beijing China
1 shared publication Hongyan Cai
The Ninth Medical Center of PLA General Hospital, Beijing 100101, China
1 shared publicationHuimin Chen
The Ninth Medical Center of PLA General Hospital, Beijing 100101, China
1 shared publicationLei Zhu
The Ninth Medical Center of PLA General Hospital, Beijing 100101, China
1 shared publication- Mei Hu
Research Department The Ninth Medical Center, Chinese PLA General Hospital Olympic Village Street Beijing China
1 shared publication
Latest Publications
- 11 October 2025
- Published by Elsevier in Life Sciences in Space Research
- Vol. 48, 143-155
Simulated Microgravity affects immune reaction to infection through altering lymphocyte differentiation, cytokine secretion, and macrophage polarization
- 11 October 2025
- Published by Elsevier in Life Sciences in Space Research
- Vol. 48, 143-155
Simulated Microgravity affects immune reaction to infection through altering lymphocyte differentiation, cytokine secretion, and macrophage polarization
- 7 August 2025
- Published by Wiley in Microbiology and Immunology
- Vol. 69 (10) , 522-531
miR‐186 Regulates Septic Hyperinflammation and Predicts Sepsis
Sepsis is a life‐threatening condition caused by infection‐induced immune dysregulation. Clinically distinguishing sepsis from infection remains to be a challenge due to overlapping clinical features. Although miR‐186 regulates cell proliferation and apoptosis, and was predicted to target immune‐related genes, its role in sepsis is unclear. We retrospectively enrolled 21 infected patients and 20 sepsis patients. The miR‐186 level in blood cells was detected using real‐time PCR. Cytokine concentrations and lymphocyte subpopulation proportions were determined using flow cytometry. Clinical data were retrieved from medical records. The diagnostic ability of miR‐186 was compared with procalcitonin and lactate using the receiver operating characteristic (ROC) curve. miR‐186 was inhibited in human umbilical vein endothelial cells (HUVECs) and mice, followed by measurement of cytokine expression using real‐time PCR and flow cytometry. The expression level of miR‐186 was significantly higher in septic patients than in infected patients. miR‐186 showed relatively better diagnostic performance for sepsis than procalcitonin and lactate. The in vitro assay showed that LPS enhanced miR‐186 expression under a dose‐dependent manner. In vitro miR‐186 inhibition in HUVECs inhibited IL‐1β, IL‐6, and IL‐8 expression. In vivo miR‐186 inhibition significantly lowered IL‐1β concentration and natural killer cell ratio. In this study, we found that miR‐186 is significantly upregulated in sepsis and plays a regulatory role in cytokine expression, highlighting its potential as a diagnostic biomarker for sepsis.
- 7 August 2025
- Published by Wiley in Microbiology and Immunology
- Vol. 69 (10) , 522-531
miR‐186 Regulates Septic Hyperinflammation and Predicts Sepsis
Sepsis is a life‐threatening condition caused by infection‐induced immune dysregulation. Clinically distinguishing sepsis from infection remains to be a challenge due to overlapping clinical features. Although miR‐186 regulates cell proliferation and apoptosis, and was predicted to target immune‐related genes, its role in sepsis is unclear. We retrospectively enrolled 21 infected patients and 20 sepsis patients. The miR‐186 level in blood cells was detected using real‐time PCR. Cytokine concentrations and lymphocyte subpopulation proportions were determined using flow cytometry. Clinical data were retrieved from medical records. The diagnostic ability of miR‐186 was compared with procalcitonin and lactate using the receiver operating characteristic (ROC) curve. miR‐186 was inhibited in human umbilical vein endothelial cells (HUVECs) and mice, followed by measurement of cytokine expression using real‐time PCR and flow cytometry. The expression level of miR‐186 was significantly higher in septic patients than in infected patients. miR‐186 showed relatively better diagnostic performance for sepsis than procalcitonin and lactate. The in vitro assay showed that LPS enhanced miR‐186 expression under a dose‐dependent manner. In vitro miR‐186 inhibition in HUVECs inhibited IL‐1β, IL‐6, and IL‐8 expression. In vivo miR‐186 inhibition significantly lowered IL‐1β concentration and natural killer cell ratio. In this study, we found that miR‐186 is significantly upregulated in sepsis and plays a regulatory role in cytokine expression, highlighting its potential as a diagnostic biomarker for sepsis.